JACOBIO PHARMACEUTICALS GROUP CO., LTD. 1167 2021 6 30 SHP2 SHP2 JAB-3068 JAB-3312 RAS JAB-3312 SHP2 JAB-3312PD-1 MEKIb/IIa FDA 2020 12INDIND 2021 5 2021 5 AbbVie 2021 720 AbbVie JAB-3068 SHP2 JAB-3068I JAB-3068IIa 1
2020 12 JAB-3068PD-1 I/IIa2021 4 JAB-8263 BET JAB-8263 BET MYC JAB-8263I 2021 4 2020 11 JAB-21822 KRAS G12C JAB-21822 KRAS G12C 2021 5 FDA JAB-21822 KRAS G12C IND JAB-21822 I 2021 7 JAB-21822 PD-12021 8 IND IND JAB-BX102CD73 2021 9 FDAJAB-BX102PD-1 IND 2021 JAB-6343 4(FGFR4) 2021IND JAB-2485 RB1 Aurora A 2021IND JAB-24000 2021 3IND JAB-BX300 RAS2021 3IND JAB-22000 KRAS G12D 20222023 IND 2
JAB-26000 20222023 IND JAB-23000 KRAS G12V 20232024 IND 2021 4 2021 3 2021 8Hebecell 25,000,000HebecellHebecell 1,321,257 A Hebecell 19.74% Hebecell 2021 8 31 2021 6 30 57.7 AbbVieSHP2 2020 6 30 71.0 50.771.4% 2021 6 30 121.7 2020 6 30 12.4 6.149.2% 2021 6 30 18.5 3
2020 6 30 733.12021 6 30 2020 6 30 810.9 2021 6 30 136.6 4
PTPs Kirsten2KRAS 2015 7 AbbVie Ireland Unlimited Company AbbVie AbbVie Inc. ABBV Src2 2 SHP2 KRAS MYCMYCRB 1(PD-(L)1) 50% PTPsSHP2 GTP KRAS I/IIIND 5
2021 8 26IND IND I IIa JAB-3068 SHP2 PD-1 mab ESCC HNSCC NSCLC ESCC HNSCC NSCLC IND2021 4 JAB-3312 SHP2 PD-1 mab MEKi KRAS G12Ci 3 BRAF NF1 LOF NSCLC HNSCC ESCC KRASCRC KRAS G12C ** * + + + IND2021 5 IND2021 5 IIa 2021 Ib/IIa 2021 JAB-8263 BET (MYC) JAB-21822 KRAS G12C (SHP2/RAS) PD-1 mab SHP2i EGFR MF AML NSCLC CRC NSCLC CRC NSCLC NSCLC NSCLC NSCLC CRC CRC * * + + + IND2021 IND2021 4 2021 5IND IND2021 7 2021 8IND 2021 8IND 2021 2022 2022 2022 2022 2022 IND IND IND JAB-BX102 JAB-6343 JAB-2485 JAB-24000 JAB-BX300 JAB-26000 JAB-22000 CD73 mab (I/O) FGFR4 (RTK) Aurora A (MYC/RB) RAS (I/O) KRAS G12D (RAS) PD-(L)1 CRC CRPC HCC RB1 NSCLC HNSCC PDAC CRC SCLC HNSCC ESCC PDAC CRC NSCLC GLP-tox DS/DP GMP GLP-tox GMP API GLP-tox DS/DP GMP 2021 3 IND 2021 3 IND 2021 1 2020 11 IND 2021 IND 2021 IND 2021 IND 2022 IND 2022 IND 20222023 ) IND 20222023 ) * RP2DIIa + IND Ib/IIa 6
KRAS SHP2 RASKRAS SHP2 KRAS JAB-3068 JAB-3312 SHP2JAB-3068 JAB-3312 RAS SHP2 JAB-3068 FDA IND SHP2JAB-3068 JAB- 3312 FDA SHP2 JAB-3068 JAB-3312 JAB-3068 JAB-3068 I/IIaI I I II (RP2D) I/IIaJAB-3068 JAB-3068 JAB-3068 IIa IIaJAB-3068 JAB-3068 PD-1mAb 2020 12JAB-3068 PD-1 I/IIa 2021 4 7
JAB-3312 IJAB-3312 2020 7 JAB-33123 BRAF NF1 LOF JAB-3312 PD-1mAb MEK KRAS G12C Ib/IIaJAB-3312 PD-1 MEK2020 12 FDAIND2021 5 IND 2021 5 AbbVie 2021 720 AbbVie JAB-3312 KRAS G12C AbbVie 2020 5AbbVie SHP2JAB-3068 JAB-3312 AbbVie AbbVie SHP2 SHP22020 9 SHP2 AbbVie SHP2 SHP2 8
JAB-8263 JAB-3312PD-1Pembrolizumab MEK BinimetinibIb/IIa AbbVie 2021 7 20 AbbVie AbbVie JAB-8263 BET MYC JAB-8263 MYC NMC NSCLC SCLC CRPC ESCC(MF)(AML) JAB-82632020 7 FDA IND 2020 11MF AML JAB-8263 IND 2020 11 2021 4 JAB-21822 KRAS JAB-21822 KRAS G12CSHP2 EGFR JAB-21822PK (Amgen) MiratiKRAS G12C 2021 5 FDA JAB-21822 KRAS G12C IND JAB-21822 I 2021 7JAB-21822 PD-12021 8 IND JAB-21822 SHP2EGFR 9
IND RAS MYC RB JAB-BX102 JAB-BX102CD73 PD-1CRC JAB-BX102 GMP 2021 9FDAJAB-BX102 PD-1IND2021 IND JAB-6343 JAB-6343 (HCC) 4(FGFR4) JAB-6343 FGF19 HCC GLPGMP2021 IND JAB-2485 JAB-2485 Aurora A RB1SCLC RB1 (SCLC) (TNBC) RB1 RB1 Aurora AJAB-2485 GLPGMP2021 IND JAB-24000 JAB-24000 NSCLC HNSCC JAB- 24000 SHP2KRAS 2020 5 2021 3 IND I JAB-24000 JAB-BX300 JAB-BX300 RAS KRAS 2019 9 2021 3 IND I JAB-BX300 10
JAB-22000 JAB-22000KRAS G12D 2020 11 20222023 IND KRAS G12D JAB-22000 JAB-26000 JAB-26000 SCLC HNSCC ESCC 2021 1 20222023 IND I JAB-26000 JAB-23000 JAB-23000KRAS G12VJAB-23000 20232024 IND 2021 3 2021 4 2021 8Hebecell 25,000,000HebecellHebecell 1,321,257 A Hebecell 19.74% Hebecell 2021 8 31 2021 6 30 (i)(ii) (iii)(iv) (v)(vi) (vii) (viii)101 PCT73 11
2019 2019 COVID-19 COVID-19 COVID-19 12
SHP2 KRAS SHP2KRAS G12C 2021 SHP2 KRAS SHP2JAB-3312 PD-1 MEKI/II 2021 5 JAB-3312 KRAS G12C 2021 4 I/II JAB-3068 PD-1 SHP2 KRAS G12CJAB-21822KRAS G12C I/IIIND2021 5 FDA2021 7 JAB-21822PD-12021 8 INDJAB-21822 SHP2 EGFR JAB-21822 G12D(JAB-22000) G12V(JAB-23000) KRAS CRC NSCLC JAB-22000 20222023 IND JAB-23000 20232024 IND RASJAB-BX300 KRAS JAB-BX300 IND 2022 IND SHP2 KRAS 13
SHP2 KRAS BET JAB-82632020 11 2021 4 IND2021 IND JAB-21822 KRAS G12C 2021 3 IND JAB-BX100 CD73JAB-2485 Aurora A JAB-6343 FGFR4JAB-24000 JAB-BX300IND 2022 JAB-24000 JAB-BX300IND 2021 4 14
GMP 20,000 2023 AbbVieSHP2 Hebecell 18A.08(3) 15
6 30 2021 2020 % % 57,689 100 2020 6 302021 6 30 57.7 AbbVie SHP2 6 30 2021 2020 % % SHP2 53,133 100 SHP2 2021 6 30 53.1 SHP2 2020 6 30 AbbVie SHP2 6 30 2021 2020 % % 4,556 100 2020 6 30 2021 6 30 4.6 16
6 30 2021 2020 3,624 3,280 100 3,624 3,380 2020 6 30 3.4 2021 6 30 3.60.3 6 30 2021 2020 (14,631) 1,069 2,701 (11,930) 1,069 2021 6 30 2021 6 3014.6 2020 6 30 1.115.72021 6 30 14.6 2021 6 302020 6 30 2021 6 302.7 17
18 6 30 2021 2020 51,994 26,190 38,184 23,516 18,985 9,359 3,765 4,042 8,732 7,905 121,660 71,012 2020 6 30 71.0 50.72021 6 30 121.7 (i) 25.8 (ii) 14.7 (iii) 9.6 6 30 2021 2020 12,379 7,136 961 1,895 308 831 516 4,880 1,996 18,528 12,374 2020 6 30 12.4 6.12021 6 30 18.5 2020 6 30 1.85.8 2021 6 30 7.6
20202021 6 30 6 30 2021 2020 (136,597) (810,904) 733,079 10,829 6,806 516 (125,768) (70,503) 19
6 30 2021 2020 (121,660) (71,012) 6,748 6,244 (114,912) (64,768) 6 30 2021 2020 (18,528) (12,374) 3,047 562 516 (15,481) (11,296) 2021 6 30114.8 2020 6 30 42.8 2021 6 30182.1 2020 6 30252.2 2021 6 30 2021 6 30 119.6 2020 6 3043.1 (i)2020 6 30 C+ 182.5 (ii)2021 6 30 132.8 20
2021 6 30 2021 6 301,612.4 2020 12 31 1,627.4 AbbVie 159.4AbbVie 2021 6 2021 7 2021 1 13 11,808,300 12.24% 158.7 2021 6 30 162019 1 1 16 2021 6 30 2020 12 31 2021 6 30 12.7 2021 6 302020 12 31 0.8 0.5 21
2021 6 302020 2021 6 30 2021 6 30 1,738.6 2020 12 31 1,741.52.9 2021 6 30 2132021 6 30 59.3 2020 6 30 30.7 22
2021 6 30 2021 6 30 A.2.1 A.2.1 2021 6 30 23
3.21 3.22 C.3 2021 1 13 2021 1 1811,808,300 2021 6 30 1,421.8 1,183.1 2025 24
2021 6 3093.9 2021 6 30 2021 6 30 JAB-3068 44% 520.6 520.6 JAB-3312 18% 213.0 213.0 JAB-3068 JAB-3312 4% 47.3 47.3 JAB-8263 10% 118.3 6.4 111.9 JAB-21822 IND 8% 94.6 33.3 61.3 4% 47.3 37.0 10.3 GMP 8% 94.6 94.6 4% 47.4 17.2 30.2 100% 1,183.1 93.9 1,089.2 25
(www.hkexnews.hk) (www.jacobiopharma.com) 2021 26
6 30 2021 2020 3 57,689 4 (53,133) 4,556 4 (121,660) (71,012) 4 (18,528) (12,374) 3,624 3,380 (11,930) 1,069 (143,938) (78,937) 7,644 1,831 (303) (719) 7,341 1,112 (733,079) (136,597) (810,904) 5 (136,597) (810,904) (136,597) (810,896) (8) (136,597) (810,904) 6 (0.18) (2.42) 27
6 30 2021 2020 (136,597) (810,904) (38) (5) (3,518) (38) (3,523) (136,635) (814,427) (136,635) (814,419) (8) (136,635) (814,427) 28
2021 2020 6 30 12 31 35,422 30,261 5,648 3,868 1,088 1,171 17,292 16,702 59,450 52,002 3 28,349 171,413 8 159,374 10,631 15,743 2,636 784 9 1,612,373 1,627,408 1,813,363 1,815,348 1,872,813 1,867,350 510 502 3,979,387 3,846,602 111,557 100,728 (2,298,229) (2,161,632) 1,793,225 1,786,200 1,793,225 1,786,200 29
2021 2020 6 30 12 31 2,583 2,011 2,254 5,261 4,837 7,272 10 48,243 28,281 16,417 37,376 10,091 8,221 74,751 73,878 79,588 81,150 1,872,813 1,867,350 30
1 2018 6 1 1961 322 Walkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands 2020 12 21 2021 8 31 2 34 2020 12 31 2020 12 31 (a) 2021 1 1 7 4 16 31
(b) 16 2022 1 1 37 2022 1 1 3 2022 1 1 20182020 20182020 2022 1 1 1 2023 1 1 17 2023 1 1 10 28 3 CODM CODM (a) CODM CODM (b) 2021 6 30 57,689,000 32
(c) 6 30 2021 2020 57,689 6 30 2021 2020 57,689 (d) 2021 6 30 2020 12 31 28,349 171,413 28,349 171,413 4 33 6 30 2021 2020 91,448 26,190 59,274 30,652 21,057 9,359 4,885 4,873 4,728 6,383 4,162 1,758 3,658 2,002 990 130 467 300 516 2,652 1,223 193,321 83,386
5 6 30 2021 2020 (a) 2 8.25% 16.5% 20212020 6 30 21% 20212020 6 308.00% 25% HNTE 20212020 6 3015% 2018 175% 34
6 (a) 6 30 2021 2020 (136,597) (810,896) (i) 746,365 335,508 (ii) (0.18) (2.42) (i) 2020 11 30 53,000 347,000 530,542,224 2020 6 30 (ii) (b) 20212020 6 30 20212020 6 30 7 2021 6 302020 35
8 2021 6 30 2020 12 31 159,374 90 24,612,000159,374,000 2021 6 2021 7 9 2021 6 30 2020 12 31 899,382 98,486 319,174 431,188 393,817 1,097,734 1,612,373 1,627,408 36
2021 6 30 2020 12 31 1,612,373 1,627,408 (195,747) (a) (7,222) (1,245) 1,605,151 1,430,416 (a) 10 2021 6 30 2020 12 31 1 48,203 28,004 12 237 23 40 40 48,243 28,281 37
AbbVie AbbVie Ireland Unlimited Company2020 7 19 AbbVie Inc. ABBV AML BET BET MYC CCND1 BCL2L1 CD73 5 AMP CD73 T 2018 6 1 JACOBIO (CAY) PHARMACEUTICALS CO., LTD. 1167 A JAB-3068 CRPC EGFR ESCC FPI 38
GLP-tox GLP GMP GMP GMP Hebecell Hebecell Holding Limited IND KRAS G12X KRAS12 2020 12 21 2020 12 21 GEM MEK MAPKK MAPK 39
NF1 17 NF1 NMC NSCLC PD-1 1T B PD-1 T T PD-1 T PD-(L)1 PD-11 T T I Ib/IIa Ib/IIa Ib/ IIa IIa Ia IIbIII II 2020 12 9 RAS GDP/GTP GTP 40
2021 6 30 0.0001 FDA 2021 8 31 41